Marker Therapeutics, Inc. (MRKR)
0.8928
0.00 (0.00%)
USD |
NASDAQ |
Nov 06, 16:00
0.9166
+0.02
(+2.67%)
Pre-Market: 20:00
Marker Therapeutics Cash from Operations (Quarterly) : -3.716M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.716M |
| March 31, 2026 | -1.404M |
| December 31, 2025 | -1.900M |
| September 30, 2025 | -2.736M |
| June 30, 2025 | -1.878M |
| March 31, 2025 | -5.500M |
| December 31, 2024 | -4.703M |
| September 30, 2024 | 1.198M |
| June 30, 2024 | -3.568M |
| March 31, 2024 | -3.837M |
| December 31, 2023 | -2.368M |
| September 30, 2023 | -1.128M |
| June 30, 2023 | -7.057M |
| March 31, 2023 | -5.888M |
| December 31, 2022 | -6.305M |
| September 30, 2022 | -7.646M |
| June 30, 2022 | -0.7947M |
| March 31, 2022 | -12.23M |
| December 31, 2021 | -4.858M |
| September 30, 2021 | -6.516M |
| June 30, 2021 | -6.910M |
| March 31, 2021 | -8.996M |
| December 31, 2020 | -6.219M |
| September 30, 2020 | -4.239M |
| June 30, 2020 | -4.352M |
| Date | Value |
|---|---|
| March 31, 2020 | -4.050M |
| December 31, 2019 | -4.561M |
| September 30, 2019 | -5.664M |
| June 30, 2019 | -4.179M |
| March 31, 2019 | -3.880M |
| December 31, 2018 | -6.163M |
| September 30, 2018 | -3.572M |
| June 30, 2018 | -2.399M |
| March 31, 2018 | -2.346M |
| December 31, 2017 | -2.478M |
| September 30, 2017 | -2.025M |
| June 30, 2017 | -2.012M |
| March 31, 2017 | -1.924M |
| December 31, 2016 | -1.754M |
| September 30, 2016 | -1.972M |
| June 30, 2016 | -1.954M |
| March 31, 2016 | -0.8298M |
| December 31, 2015 | -0.851M |
| September 30, 2015 | -1.665M |
| June 30, 2015 | -0.8132M |
| March 31, 2015 | -1.014M |
| December 31, 2014 | -0.6692M |
| September 30, 2014 | -0.9065M |
| June 30, 2014 | -0.238M |
| March 31, 2014 | -0.3735M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Rigel Pharmaceuticals, Inc. | 30.65M |
| ACADIA Pharmaceuticals, Inc. | -- |
| Alnylam Pharmaceuticals, Inc. | 340.98M |
| Anika Therapeutics, Inc. | -0.684M |
| Savara, Inc. | -29.75M |
Cash from Operations (Quarterly) Related Metrics
| Free Cash Flow | -9.756M |
| Free Cash Flow Per Share (Quarterly) | -0.1924 |
| Free Cash Flow to Equity (Quarterly) | -3.716M |
| Free Cash Flow to Firm (Quarterly) | -3.716M |
| Free Cash Flow Yield | -60.66% |